Epigenetic Silencing and Resistance to Imatinib Mesylate in CML

2006 ◽  
Author(s):  
Jean-Pierre Issa
Keyword(s):  
Imatinib Mesylate ◽  
Epigenetic Silencing

scholarly journals HOXA4Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Marjanu Hikmah Elias ◽  
Abdul Aziz Baba ◽  
Azlan Husin ◽  
Sarina Sulong ◽  
Rosline Hassan ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Imatinib Mesylate ◽  
Myeloid Leukemia ◽  
Clinical Problem ◽  
Promoter Hypermethylation ◽  
Epigenetic Silencing ◽  
Epigenetic Mechanism ◽  
High Resolution Melt ◽  
High Resolution Melt Analysis ◽  
Development Of Resistance

Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients has emerged as a significant clinical problem. The observation that increased epigenetic silencing of potential tumor suppressor genes correlates with disease progression in some CML patients treated with IM suggests a relationship between epigenetic silencing and resistance development. We hypothesize that promoter hypermethylation ofHOXA4could be an epigenetic mechanism mediating IM resistance in CML patients. Thus a study was undertaken to investigate the promoter hypermethylation status ofHOXA4in CML patients on IM treatment and to determine its role in mediating resistance to IM. Genomic DNA was extracted from peripheral blood samples of 95 CML patients (38 good responders and 57 resistant) and 12 normal controls. All samples were bisulfite treated and analysed by methylation-specific high-resolution melt analysis. Compared to the good responders, theHOXA4hypermethylation level was significantly higher (P=0.002) in IM-resistant CML patients. On comparing the risk,HOXA4hypermethylation was associated with a higher risk for IM resistance (OR 4.658; 95% CI, 1.673–12.971;P=0.003). Thus, it is reasonable to suggest that promoter hypermethylation ofHOXA4gene could be an epigenetic mechanism mediating IM resistance in CML patients.

Therapeutic interest of Imatinib Mesylate in osteosarcoma

2013 ◽  
Author(s):  
Berengere Gobin ◽  
Gatien Moriceau ◽  
Benjamin Ory ◽  
Regis Brion ◽  
Francoise Redini ◽  
...  
Keyword(s):  
Imatinib Mesylate
Sign in / Sign up

Export Citation Format

Share Document